SEARCH

SEARCH BY CITATION

References

  • Barrett-Connor E, Grady D, Sasheyi A, Anderson PW, Cox DA, Hoszowski K, et al., Harper KD MORE Investigators (Multiple Outcomes of Raloxifene Evaluation) randomized trial (2002). Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287: 847857.
  • Barrett-Connor E, Mosal L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al., Raloxifene Use for the Heart (RUTH) Trial Investigator (2006). Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New Engl J Med 355: 125137.
  • Barton M, Cremer J, Mügge A (1998). 17β-Estradiol acutely improves endothelium-dependent relaxation to bradykinin in isolated human coronary arteries. Eur J Pharmacol 362: 7376.
  • Bell DR, Rensberger HJ, Koritnik DR, Koshy A (1995). Estrogen pretreatment directly potentiates endothelium-dependent vasorelaxation of porcine coronary arteries. Am J Physiol 268: H377H383.
  • Chan HY, Yao X, Tsang SY, Bourreau JP, Chan FL, Huang Y (2002). Isoproterenol amplifies 17β-estradiol-mediated vasorelaxation: role of endothelium/nitric oxide and cyclic AMP. Cardiovasc Res 53: 627633.
  • Chan YC, Leung FP, Yao X, Lau CW, Vanhoutte PM, Huang Y (2005). Raloxifene relaxes rat pulmonary arteries and veins: roles of gender, endothelium and antagonism of Ca2+ influx. J Pharmacol Exp Ther 312: 12661271.
  • Colacurci N, Manzella D, Fornaro F, Carbonella M, Paolisso G (2003). Endothelial function and menopause: effects of raloxifene administration. J Clin Endocrinol Metab 88: 21352140.
  • Figtree GA, Lu Y, Webb CM, Collins P (1999). Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100: 10951101.
  • Gaynor JS, Monnet E, Selzman C, Parker D, Kaufman L, Bryant HU et al. (2000). The effect of raloxifene on coronary arteries in aged ovariectomized ewes. J Vet Pharmacol Ther 23: 175179.
  • Gilligan DM, Quyyumi AA, Cannon RO (1994). Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 89: 25452551.
  • Griffiths KA, Sader MA, Skilton MR, Harmer JA, Celermajer DS (2003). Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease. J Am Coll Cardiol 42: 698704.
  • Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO (1997). The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 96: 27952801.
  • Leung FP, Yao X, Lau CW, Ko WH, Lu L, Huang Y (2005). Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx. Am J Physiol Renal Physiol 289: F137F144.
  • Leung HS, Seto SW, Kwan YW, Leung FP, Au ALS, Yung LM et al. (2007). Endothelium-independent relaxation to raloxifene in porcine coronary artery. Eur J Pharmacol 555: 178184.
  • Leung HS, Yao X, Leung FP, Ko WH, Chen ZY, Gollasch M et al. (2006). Cilnidipine, a slow-acting Ca2+ channel blocker, induces relaxation in porcine coronary artery: role of endothelial nitric oxide and [Ca2+]i. Br J Pharmacol 147: 5563.
  • Morello KC, Wurz GT, DeGregorio MW (2003). Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42: 361372.
  • Ogita H, Node K, Asanuma H, Sanada S, Liao Y, Takashima S et al. (2002). Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart. J Am Coll Cardiol 40: 9981005.
  • Ogita H, Node K, Liao Y, Ishikura F, Beppu S, Asanuma H et al. (2004). Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice. Hypertension 43: 237242.
  • Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F et al. (2001). Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 21: 15121519.
  • Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL (2003). Raloxifene and endothelial function in healthy postmenopausal women. Am J Obstet Gynecol 188: 304309.
  • Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT (2003). The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drugs Ther 17: 319323.
  • Simoncini T, Genazzani AR, Liao JK (2002). Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105: 13681373.
  • Snyder KR, Sparano N, Malinowski JM (2000). Raloxifene hydrochloride. Am J Health Syst Pharm 57: 16691675.
  • Tsang SY, Yao X, Essin K, Wong CM, Chan FL, Gollasch M et al. (2004). Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels. Stroke 35: 17091714.
  • Wang X, Chu W, Lau F, van Breemen C (1995). Bradykinin potentiates acetylcholine induced responses in native endothelial cells from rabbit aorta. Biochem Biophys Res Commun 213: 10611067.
  • Wang X, Chu W, van Breemen C (1996). Potentiation of acetylcholine-induced responses in freshly isolated rabbit aortic endothelial cells. J Vasc Res 33: 414424.
  • Yao X, Huang Y (2003). From nitric oxide to endothelial cytosolic Ca2+: a negative feedback control. Trends Pharmacol Sci 24: 263266.
  • Zhang RZ, Yang Q, Yim AP, Huang Y, He GW (2004). Different role of nitric oxide and endothelium-derived hyperpolarizing factor in endothelium-dependent hyperpolarization and relaxation in porcine coronary arterial and venous system. J Cardiovasc Pharmacol 43: 839850.
  • Zoma WD, Baker RS, Clark KE (2000). Coronary and uterine vascular responses to raloxifene in the sheep. Am J Obstet Gynecol 182: 521528.